Press Releases
Alzheon Announces Presentations at Two Upcoming Investor Conferences
FRAMINGHAM, Mass., November 12, 2015 – Alzheon, Inc., a clinical-stage biopharmaceutical company focused on developing new medicines for patients suffering from Alzheimer’s disease and other neurological and psychiatric disorders, [...]
Alzheon Announces Efficacy Outcomes from Two Prior Tramiprosate Phase 3 Studies
Patients with Mild to Moderate Alzheimer’s Disease and APOE4/4 Genotype ShowedRobust and Sustained Efficacy on Cognitive and Functional Co‐Primary Outcomes over 78 weeks with Favorable Safety [...]
Alzheon Announces Initiation of Clinical Studies with ALZ‐801 Bridging to Pivotal Phase 3 Study in Alzheimer’s Disease
Phase 1b Multiple Dose‐Ranging Study and Tablet Bioequivalence Study Will Provide Clinical Dose and Tablet Formulation Data to Support ALZ‐801 Phase 3 Program FRAMINGHAM, Mass., November [...]
Alzheon Appoints Susan Abushakra, M.D., as Chief Medical Officer
FRAMINGHAM, Mass., September 9, 2015 – Alzheon, Inc., a clinical-stage biopharmaceutical company focused on developing new medicines for patients suffering from Alzheimer’s disease and other neurological [...]
Alzheon Establishes New Corporate Headquarters
Expanded Facility Supports Business and Clinical Operations to Drive Future Pivotal Study of ALZ-801 in Patients with Alzheimer’s Disease FRAMINGHAM, Mass., April 8, 2015 -- Alzheon, [...]
Alzheon Announces $10 Million Series A Financing
Funding to Advance ALZ-801 Toward a Pivotal Clinical Study in Alzheimer’s Disease FRAMINGHAM, Mass., April 8, 2015 – Alzheon, Inc., a clinical-stage biopharmaceutical company focused on [...]